120 related articles for article (PubMed ID: 27541085)
1. Mouse models of medullary thyroid cancer and developing new targeted therapies.
Paragliola RM; Torino F; Papi G; Locantore P; Pontecorvi A; Corsello SM
Expert Opin Drug Discov; 2016 Oct; 11(10):917-9. PubMed ID: 27541085
[No Abstract] [Full Text] [Related]
2. Update on Targeted Therapy in Medullary Thyroid Cancer.
Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
[TBL] [Abstract][Full Text] [Related]
3. [New therapies in thyroid cancer].
López Mondéjar P; Galofré JC
Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
[No Abstract] [Full Text] [Related]
4. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
5. RET kinase inhibitors: a review of recent patents (2012-2015).
Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L
Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
10. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib for the treatment of thyroid cancer.
Gómez-Sáez JM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
[TBL] [Abstract][Full Text] [Related]
13. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
14. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib.
Miles DR; Wada DR; Jumbe NL; Lacy SA; Nguyen LT
Anticancer Drugs; 2016 Apr; 27(4):328-41. PubMed ID: 26825867
[TBL] [Abstract][Full Text] [Related]
16. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma.
Maxwell JE; Gule-Monroe MK; Subbiah V; Hu M; Perrier ND; Cabanillas ME; Lee JE; Graham PH; Cote GJ; Busaidy NL; Grubbs EG
Surgery; 2020 Jan; 167(1):80-86. PubMed ID: 31648931
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Spector E; Franklin MJ; Truskinovsky AM; Dudek AZ
Acta Oncol; 2010; 49(1):104-6. PubMed ID: 19711206
[No Abstract] [Full Text] [Related]
18. Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.
Marques P; Vieira Mda S; Bugalho MJ
Endocrine; 2015 May; 49(1):290-2. PubMed ID: 25022661
[No Abstract] [Full Text] [Related]
19. Targeted therapies and thyroid cancer: an update.
de la Fouchardiere C; Droz JP
Anticancer Drugs; 2011 Aug; 22(7):688-99. PubMed ID: 21200314
[TBL] [Abstract][Full Text] [Related]
20. Disseminated medullary thyroid cancer - an alternative therapeutic approach.
Wilczyńska M; Suchmiel M; Sokołowski G; Hubalewska-Dydejczyk A; Trofimiuk-Müldner M
Endokrynol Pol; 2022; 73(5):909-910. PubMed ID: 35971935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]